All News

13/02 Changes to the Composition of the Lonza Board EQ
03/02 Swiss stocks - Factors to watch on February 3 RE
29/01 Swiss trade surplus at CHF 1.036 bln in December RE
28/01 Glum Economic Sentiment Weighs on Swiss Stocks; All Eyes on US Rate Decision MT
28/01 Global markets live: Amazon, Bank of America, Oracle, Eli Lilly, Boeing… Zonebourse
28/01 Lonza Group AG, 2025 Earnings Call, Jan 28, 2026
28/01 Lonza Group: Ended 2025 on a high note Alphavalue
28/01 Lonza Group Forecasts Sustained Growth in 2026 After Sales Beat MT
28/01 Switzerland's Lonza edges closer to sale of its capsule and health ingredients business (Jan. 28) RE
28/01 Lonza Group AG Reports Earnings Results for the Full Year Ended December 31, 2025 CI
28/01 Lonza's Attributable Profit Rises in 2025 MT
28/01 Contract drug manufacturer Lonza forecasts slower sales growth for 2026 RE
28/01 Lonza Sales Grow on New Contract Momentum DJ
28/01 Lonza Group's FY25 Profit, Sales Rise MT
28/01 Swiss stocks - Factors to watch on January 28 RE
28/01 Lonza FY Sales Growth 21.7% RE
28/01 Lonza forecasts 2026 sales growth of 11-12% for core CDMO business RE
28/01 Lonza : 2025 Full-Year Alternative Performance Measures Report PU
28/01 Lonza : 2025 Full-Year Results Report PU
28/01 Lonza : 2025 Full-Year Results Presentation PU
28/01 Lonza Delivers Strong Profitable Growth in Full-Year 2025 and Successfully Completes Vacaville Site Integration EQ
28/01 Lonza Group AG Proposes Dividend for 2025 CI
28/01 Lonza Group AG Provides Earnings Guidance for 2026 CI
14/01 Lonza Group AG Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 10:30 AM
18/12 Swiss trade surplus at CHF 3.841 bln in November RE
No results for this search